

## Special Issue

# The Role of Amyloids in Neurodegenerative Diseases: Current Insights and Future Perspectives

### Message from the Guest Editors

It is well known that amyloid accumulation is a key pathological hallmark of multiple neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, or amyotrophic lateral sclerosis, among others. This Special Issue welcomes the submission of original research manuscripts or review manuscripts which focus on topics which include, but are not limited to:

- Development of novel amyloidosis animal models and comparison of existing ones;
- Reviews about the past, present, and future of anti-amyloid immunotherapies;
- Studies of the molecular mechanisms involved in amyloid overproduction or amyloid clearance in neurodegenerative diseases;
- Longitudinal studies involving amyloid biomarkers;
- Development of CAA in neurodegenerative disorders;
- Amyloid imaging studies in neurodegenerative disease patients;
- Role of glial cells in amyloid production and clearance.

---

### Guest Editors

Dr. Angela Gomez-Arboledas  
Institute for Memory Impairments and Neurological Disorders,  
University of California, Irvine, CA 92697, USA

Dr. Giedre Milinkeviciute  
Institute for Memory Impairments and Neurological Disorders,  
University of California, Irvine, CA 92697, USA

---

### Deadline for manuscript submissions

closed (31 October 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/182013](https://mdpi.com/si/182013)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).